Paraneoplastic Reflexive Panel, CSF
Also known as: PNSPAN CSF
Use
The Paraneoplastic Reflexive Panel, CSF aids in the diagnosis of paraneoplastic neurologic syndromes by evaluating for the presence of high-risk paraneoplastic antibodies in the cerebrospinal fluid (CSF). This test focuses on antibodies that can be independent of neurologic phenotype. However, phenotype-specific panels are preferred for evaluating autoimmune neurologic disease, and testing in both serum and CSF is recommended to enhance diagnostic yield.
Special Instructions
If the IFA screen is indeterminate, Neuronal Nuclear Antibodies (Hu, Ri, Yo, Tr/DNER) IgG by Immunoblot will be added. If the IFA screen is positive at 1:1 or greater, a PCCA/ANNA antibodies titer and Neuronal Nuclear Antibodies (Hu, Ri, Yo, Tr/DNER) IgG by Immunoblot will be added, with additional charges applying. Results should be interpreted in the context of the patient's clinical history and other laboratory findings.
Limitations
A negative test result does not exclude a diagnosis of autoimmune neurologic disease. False positives may occur, and the results should be interpreted along with the patient's complete clinical picture. More extensive evaluation may be necessary when certain results, like CV2 antibody, are detected, implying further screening for associated cancers such as small-cell lung cancer and thymoma.
New York Approved
Methodology
Immunoassay (Cell-based / Cytometry)
Biomarkers
LOINC Codes
- 14247-1
- 53707-6
- 94383-7
- 57750-2
- 107194-3
Result Turnaround Time
1-9 days
Related Documents
For more information, please review the documents below
Specimen
Cerebrospinal Fluid
Volume
2 mL
Minimum Volume
1 mL
Container
ARUP standard transport tube
Causes for Rejection
Contaminated, heat-inactivated, hemolyzed, or lipemic specimens
Stability Requirements
| Temperature | Period |
|---|---|
| Room Temperature | 48 hours |
| Refrigerated | 2 weeks |
| Frozen | 1 month |